细胞名称：
人黑色素瘤细胞WM115 产品规格：T25培养瓶x1；1.5ml冻存管x2
细胞数量：1x10^6；1x10^6
保存温度：37℃；-198℃
运输方式：常温保温运输；干冰运输
安全等级：1
用途限制：仅供科研3类
培养体系：DMEM高糖（不含丙酮酸钠）+10%FBS+1%三抗
培养温度：37℃
二氧化碳浓度：5%
简介：人黑色素瘤细胞WM115取自55岁女性供体，贴壁培养。
注释
Part of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:COSMIC cell lines project.
Part of:MD Anderson Cell Lines Project.
Part of:Wistar Institute melanoma cell line collection.
Microsatellite instability:Stable(MSS)(Sanger).
Omics:Deep antibody staining analysis.
Omics:Deep exome analysis.
Omics:Deep quantitative proteome analysis.
Omics:Deep RNAseq analysis.
Omics:DNA methylation analysis.
Omics:Protein expression by reverse-phase protein arrays.
Omics:SNP array analysis.
Omics:Transcriptome analysis.
Caution:The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018.The major changes were:CSF1PO:11,12->12,D18S51:17->17,21 and D8S1179:8,13->13,15.
Misspelling:WH115mel;In CGH-DB 9323-4.
基因突变
Heterozygous for BRAF p.Val600Asp(c.1799_1800delTGinsAT)(ClinVar=VCV000375939)(PubMed=15467732;Wistar).
Hemizygous for PTEN deletion(Wistar).
HLA信息
Class I
HLA-A A*02:01,29:02
HLA-B B*13:02,44:03:01
HLA-C C*06:02,16:01
Class II
HLA-DP DPB1*02:01:02,02:01:02
HLA-DQ DQB1*02:01,02:01
HLA-DR DRB1*07:01,07:01
STR信息
Amelogenin X
CSF1PO 12
D2S1338 19
D3S1358 15,18
D5S818 13
D7S820 8
D8S1179 13,15
D13S317 12,13
D16S539 11,12
D18S51 17,21
D19S433 13
D21S11 29
FGA 21,23
TH01 7,9
TPOX 8,11
vWA 15,17
参考文献
PubMed=30894373;DOI=10.1158/0008-5472.CAN-18-2747
Dutil J.,Chen Z.,Monteiro A.N.,Teer J.K.,Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res.79:1263-1273(2019)
PubMed=31068700;DOI=10.1038/s41586-019-1186-3
Ghandi M.,Huang F.W.,Jane-Valbuena J.,Kryukov G.V.,Lo C.C.,McDonald E.R.III,Barretina J.,Gelfand E.T.,Bielski C.M.,Li H.,Hu K.,Andreev-Drakhlin A.Y.,Kim J.,Hess J.M.,Haas B.J.,Aguet F.,Weir B.A.,Rothberg M.V.,Paolella B.R.,Lawrence M.S.,Akbani R.,Lu Y.,Tiv H.L.,Gokhale P.C.,de Weck A.,Mansour A.A.,Oh C.,Shih J.,Hadi K.,Rosen Y.,Bistline J.,Venkatesan K.,Reddy A.,Sonkin D.,Liu M.,Lehar J.,Korn J.M.,Porter D.A.,Jones M.D.,Golji J.,Caponigro G.,Taylor J.E.,Dunning C.M.,Creech A.L.,Warren A.C.,McFarland J.M.,Zamanighomi M.,Kauffmann A.,Stransky N.,Imielinski M.,Maruvka Y.E.,Cherniack A.D.,Tsherniak A.,Vazquez F.,Jaffe J.D.,Lane A.A.,Weinstock D.M.,Johannessen C.M.,Morrissey M.P.,Stegmeier F.,Schlegel R.,Hahn W.C.,Getz G.,Mills G.B.,Boehm J.S.,Golub T.R.,Garraway L.A.,Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=31978347;DOI=10.1016/j.cell.2019.12.023
Nusinow D.P.,Szpyt J.,Ghandi M.,Rose C.M.,McDonald E.R.III,Kalocsay M.,Jane-Valbuena J.,Gelfand E.,Schweppe D.K.,Jedrychowski M.,Golji J.,Porter D.A.,Rejtar T.,Wang Y.K.,Kryukov G.V.,Stegmeier F.,Erickson B.K.,Garraway L.A.,Sellers W.R.,Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)
